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Abstract: In vivo bioluminescent imaging (BLI) is increasingly being utilized as a method 
for modern biological research. This process, which involves the noninvasive interrogation 
of living animals using light emitted from luciferase-expressing bioreporter cells, has been 
applied  to  study  a  wide  range  of  biomolecular  functions  such  as  gene  function,  drug 
discovery and development, cellular trafficking, protein-protein interactions, and especially 
tumorigenesis,  cancer  treatment,  and  disease  progression.  This  article  will  review  the 
various bioreporter/biosensor integrations of BLI and discuss how BLI is being applied 
towards a new visual understanding of biological processes within the living organism. 
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1. Introduction 
Whole animal bioluminescent imaging (BLI) is progressively becoming more widely applied by 
investigators from diverse backgrounds because of its low cost, high throughput, and relative ease of 
operation in visualizing a wide variety of in vivo cellular events [1]. The ability to visualize cellular 
processes or other biological interactions without the requirement for animal subject sacrifice allows 
for repeated imaging and releases investigators from the constraints of considering their process of 
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interest on a ―frame-by-frame‖ basis using labeled slides. In addition, the ability to continually monitor 
a single individual reduces the amount of inter-animal variation and can reduce error, leading to higher 
resolution and less data loss. With continuing advances in the hardware and software required for 
performing these experiments,  it is  also  becoming easier for researchers  with little background in 
molecular imaging to obtain useful and detailed publication-ready images. 
The mainstays of BLI are the light generating luciferase enzymes such as firefly luciferase, Renilla 
luciferase, Gaussia luciferase, Metridia luciferase, Vargula luciferase, or bacterial luciferase [2-7]. Of 
these however, the firefly, Renilla, and bacterial luciferases are the most popular for optical imaging. 
These bioluminescent proteins are gaining preference over their fluorescent counterparts because the 
lack of endogenous bioluminescent reactions in mammalian tissue allows for near background-free 
imaging conditions whereas the prevalence of fluorescently active compounds in these tissues can 
interfere with target resolution upon exposure to the fluorescent excitation wavelengths required for 
the generation of signal output. 
2. Common Bioluminescent Reporter Proteins 
Firefly  luciferase  (FLuc)  is  the  best  studied  of  a  large  number  of  luminescent  proteins  to  be 
discovered in insects. The genes utilized in most studies are those from the common North American 
firefly,  Photinus pyralis [8]. The FLuc protein  catalyzes  the oxidation  of reduced luciferin in  the 
presence of ATP-Mg
2+ and oxygen to generate CO2, AMP, PPi, oxyluciferin, and yellow-green light at 
a wavelength  of 562 nm.  This  reaction  was  originally reported to  occur with  a quantum  yield of  
almost 90% [9], however, advances in detection technology have revealed that it is likely actually 
closer to 40% [10]. Nonetheless, the sufficiently high quantum yield of this reaction is well suited to 
use as a reporter with as few as 10
−19 mol of luciferase (2.4 ×  10
5 molecules) able to produce a light 
signal capable of being detected [11]. 
Renilla luciferase (RLuc) undergoes a similar method of action to produce bioluminescence. The 
gene  encoding  for  this  protein  was  originally  isolated  from  the  soft  coral  Renilla  reniformis  and 
displays blue-green light at a wavelength of 480 nm, however, additional red-shifted variants have 
been created as well that luminesce at higher wavelengths to promote increased tissue penetration of 
the luminescent signal. Regardless of the emission wavelength, the RLuc proteins all catalyze the 
oxidative  decarboxylation  of  its  substrate  coelenterazine  in  the  presence  of  dissolved  oxygen  and 
perform this reaction at a quantum yield of 7% [3]. Because of its dissimilar bioluminescent signal and 
substrate, RLuc is often used simultaneously with FLuc for multiple reporter studies.  
Bacterial luciferase (Lux) is distinct in function from FLuc and RLuc. Although the most studied of 
the Lux-containing species are marine bacteria from the Vibrio genus, this bioluminescent strategy is 
present among many known bacterial phyla, and in all documented examples the basic method of 
bioluminescent production is the same [12]. The Lux operon is organized in a cassette of five genes 
(luxCDABE) that work together to produce bioluminescence in an autonomous fashion at a wavelength 
of 490 nm. Lux catalyzes the production of light through oxidation of a long chain fatty aldehyde in 
the presence of oxygen and reduced riboflavin phosphate. The luciferase is a dimer formed from the 
luxA and luxB genes, while the remainder of the genes (luxCDE) are responsible for protein products 
that  catalyze  production  and  turnover  of  the  required  aldehyde  substrate  [7].  Because  of  this  Sensors 2011, 11                       
 
 
182 
self-sufficient design, Lux does not require the addition of a substrate if it is capable of being properly 
expressed in the host cell. 
The advantages and disadvantage of BLI reporter proteins are listed in Table 1. 
Table 1. Comparison of BLI reporter proteins. 
Reporter  Advantages  Disadvantages 
Firefly and 
click beetle 
luciferase 
 
 D-luciferin 
substrate 
 High sensitivity and low  
signal-to-noise ratio 
 Quantitative correlation between 
signal strength and cell numbers 
 Low background in animal 
tissues 
 Variations of firefly luciferase 
(stabilized and red-shifted) and 
click beetle luciferases (red and 
green) are available 
 Different colors allow  
multi-component monitoring 
 Requires exogenous luciferin 
addition 
 Fast consumption of luciferin 
can lead to unstable signal 
 ATP and oxygen dependent  
 Currently not practical for 
large animal models 
Renilla and 
Gaussia 
luciferase 
 
 Coelenterazine 
substrate 
 High sensitivity 
 Quantitative correlation between 
signal strength and cell numbers 
 Stabilized and red-shifted 
Renilla luciferase are available 
 Secretion of Gaussia luciferase 
allows for subject-independent 
bioluminescence measurement  
 
 Requires exogenous 
coelenterazine addition 
 Low anatomic resolution 
 Increased background due to 
oxidation of coelenterazine by 
serum 
 Oxygen dependent 
 Fast consumption of 
coelenterazine can lead to 
unstable signal 
 Currently not practical for 
large animal models 
Bacterial 
luciferase 
 High sensitivity and low  
signal-to-noise ratio 
 Quantitative correlation between 
signal strength and cell numbers 
 Fully autonomous system, no 
requirement for addition of 
exogenous substrate 
 Noninvasive 
 Stable signal 
 Rapid detection permitting 
real-time monitoring 
 Bioluminescence at 490 nm 
prone to absorptionin animal 
tissues 
 Low anatomic resolution 
 NADPH and oxygen 
dependent 
 Not as bright as other 
luciferases 
 Currently not practical for 
large animal models 
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3. Optical Properties of Biological Tissues 
The  unique  constraints  of  performing  data  collection  from  within  a  living  medium  must  be 
considered in relation to any choice of reporter system. The detection of a luminescent signal from 
within a tissue sample is dependent on several factors, including the flux of photons from the reporter, 
the total number of functional reporter cells in the sample, and the location of the reporter cells within 
the tissue sample itself [13]. In addition, the visualization of the bioluminescent signal is dependent on 
the  absorption  and  scattering  of  that  signal  prior  to  detection.  One  method  to  control  for  these 
conditions is to alter the wavelength of the reporter signal. Increasing the wavelength can both reduce 
scattering and decrease absorption because the majority of luminescent absorption is the result of 
interaction of the signal with endogenous chromophoric material. By moving to a more red-shifted 
emission wavelength, where the levels of absorption within tissue are lower, it becomes possible to 
measure a greater amount of signal intensity than would be possible from an identical reporter with a 
lower, more blue-shifted emission wavelength [14]. For this reason, it is important to consider the 
emission wavelength of a given reporter system, along with the other desired attributes of that reporter, 
prior to its introduction into any experimental design. For example, the bioluminescent signal from the 
Lux reaction is produced at 490 nm. This is relatively blue-shifted as compared to the FLuc-based 
bioluminescent probes that display their peak luminescent signal at 560 nm. The shorter wavelength of 
the Lux-based signal has a greater chance of becoming attenuated within the tissue and therefore may 
not  be  as  easily  detected  if  it  is  used  in  deeper  tissue  applications  (such  as  intraperitoneal  or 
intraorganeller  injections),  and  may  require  longer  integration  times  to  achieve  the  same  level  of 
detection as a longer wavelength reporter would when injected subcutaneously. Therefore, if short 
measurement times and low population level cell detections are the goals of a particular experiment, an 
FLuc-based reporter would be beneficial compared to a Lux-based reporter despite potential problems 
introduced through substrate administration in the FLuc system. However, if a near surface detection 
of large cell populations (such as a subcutaneous tumor) was the end goal, the effects of absorption and 
scattering could be overcome by the depth and position of the reporter, thus allowing for selection of 
the more blue-shifted Lux reporter system. 
4. Imaging Equipment 
The challenge of detecting and locating bioluminescent light emissions from within living subjects 
has  been  met  by  several  commercial  suppliers  of  in  vivo  imaging  equipment  (Table  2).  A  basic 
imaging system consists of a light-tight imaging chamber into which the subject is placed and a high 
quantum efficiency charged coupled device (CCD) camera, usually super cooled to less than −80 ° C to 
reduce thermal noise, that collects emitted light. The camera typically first takes a photographic image 
of the subject followed by a bioluminescent image. When superimposed, regions of bioluminescence 
become mapped to the subject’s anatomy for pinpoint identification of source emissions. Acquisition 
times can range from a few seconds to several minutes depending on signal strength. Software displays 
the image in a pseudo colored format and provides the tools needed to quantify, adjust, calibrate, and 
background correct the resulting image. Integrated gas anesthesia systems, heated stages, and isolation 
chambers are typically available to accommodate animal handling. Sensors 2011, 11                       
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Table 2. Commercial manufacturers of in vivo imaging systems. 
Company  URL 
Caliper Life Sciences  http://www.caliperls.com/tech/optical-imaging/ 
Berthold Technologies  http://www.berthold.com/ww/en/pub/home.cfm 
Carestream  http://www.carestreamhealth.com/in-vivo-imaging-
systems.html 
Photometrics  http://www.photometrics.com/ 
Li-Cor Biosciences  http://www.licor.com/index.jsp 
Cambridge Research & Instrumentation  http://www.cri-inc.com/index.asp 
UVP  http://www.uvp.com/ 
 
The technology incorporated into in vivo imaging systems is rapidly advancing to meet user needs 
in a greater diversity of application backgrounds. CCD cameras are being replaced by more sensitive 
intensified  CCD  (ICCD)  and  electron  multiplying  CCD  (EMCCD)  cameras  that  can  manage 
acquisition times of millisecond durations. These fast processing times along with powerful software 
now  permit  real-time  tracking  of  conscious,  moving  subjects  (see,  for  example,  the  IVIS  Kinetic 
system from Caliper Life Sciences). Anesthesia can have dramatic, unknown, and interfering effects 
on  animals,  and  the  ability  to  image  in  its  absence  is  a  major  step  forward  in  in  vivo  imaging 
technology.  However,  these  newer  imaging  systems  still  remain  far  too  expensive  for  the  typical 
researcher and to date most imaging is still performed on anesthetized animals. Imaging systems are 
additionally  becoming  better  integrated  with  existing  medical  technologies  for  multi-parameter 
analyses. For example, electrocardiogram (ECG), X-ray, or computed tomography (CT) procedures 
can operate in parallel with imaging acquisition. The ability of software to overlay and map these data 
to the bioluminescent image offers unique opportunities to visualize physiological status and kinetics. 
The major drawback of in vivo imaging systems is its limited depth penetration under whole animal 
imaging conditions. In most cases, using a CCD camera to image luminescent or fluorescent signals at 
depths beyond a few centimeters produces inconsistent results. Without major advances in imaging 
sensitivity, either with the camera systems, the internal signal, or almost certainly both in tandem,  
in vivo imaging applications may become limited solely to small animals and the translational leap to 
humans will never occur. Rather than relying on a camera to visualize the signal externally, it may be 
feasible  and  potentially  more  practical  to  monitor  the  signal  internally  using  implantable  sensors. 
Although not yet a viable technology, proof-of-concept microluminometer integrated circuits of only a 
few  square  millimeters  in  size  have  been  developed  and  validated  for  bioluminescent  signal  
acquisition  [15].  These  so-called  bioluminescent  bioreporter  integrated  circuits,  or  BBICs,  were 
specifically designed for capturing the 490 nm bioluminescent light signal emitted by the bacterial Lux 
proteins,  and  accommodated  on-chip  transmitters  for  wireless  data  transmission.  Effectively 
interfacing the microluminometers with the luciferase reporter systems, maintaining reporter viability, 
and implanting the chips would remain challenging, as would the regulatory and safety constraints 
associated with any human implantation experimental approaches. 
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5. Imaging Modalities 
5.1. Steady-State Bioluminescent Imaging 
The classical hallmark of BLI is steady state imaging, a process whereby bioluminescently tagged 
cells are imaged over time to determine if light output is increasing or decreasing compared to the 
initial state. In this type of imaging, either a gain or loss of signal can be the desired result depending 
on the experimental design. Commonly, bioluminescent cells are injected into an animal model to 
determine the kinetics of tumorigenesis and growth. The use of BLI as a substitute for mechanical or 
histological measurement of tumors has increased rapidly in recent years as it does not entail high 
levels  of  animal  subject  sacrifice  nor  tedious  histological  analysis,  and  can  overcome  the  loss  of 
accuracy associated with physical analysis due to the contribution of edema and necrotic centers to 
overall tumor size [16]. 
By monitoring tumor growth using BLI, an investigator can track changes within individual animals 
over  time  without  requiring  the  subject  to  be  sacrificed.  This  reduces  the  amount  of  intra-animal 
variability and can improve the detection of significant results. Kim and colleagues have recently 
demonstrated the effectiveness and resolution of the newest generation of these reporters designed for 
tumor detection. By injecting codon-optimized FLuc transfected 4T1 mouse mammary tumor cells 
subcutaneously, they were able to image single bioluminescent cells at a background ratio of 6:1 [17]. 
This type of resolution will allow researchers to continuously monitor cancer development from a 
single cell all the way to complete tumor formation. 
In  the  opposite  direction,  decreases  in  bioluminescent  expression  can  be  used  to  quickly  and 
efficiently perform drug efficacy screening.  The same logistical concerns that have propelled BLI 
forward as the tool for choice for tumor monitoring are also making it the preferred choice for the 
screening of new compounds directed at tumor suppression or infection control. In addition, the use of 
mixed  culture  or  whole  animal  models  can  more  closely  mimic  the  target  microenvironmental 
conditions that may alter the compound’s activity. As one example, McMillin et al. [18] illustrated that 
high throughput scalable mixed cell cultures with FLuc tagged cancer cells can identify anti-cancer 
drugs that are specifically effective in the tumor microenvironment early in the discovery pipeline, 
thereby aiding in their prioritization for further study in ways not previously possible. 
5.2. Multi-Reporter Bioluminescent Imaging 
In a basic experimental design, multi-reporter BLI is performed by simultaneously monitoring for 
expression of two or more divergent luciferase proteins. This is made possible because all of the 
characterized luciferase proteins have divergent bioluminescent emission wavelengths. This type of 
experimental  design  is  especially  useful  when  used  to  monitor  potentially  co-dependent,  or  
inter-dependent protein expression such as that expressed during the maintenance of circadian rhythm. 
Here, the expression of multiple genes can be monitored in real time, without the need to expose cells 
to potentially influential doses of excitation light wavelengths as would be required for imaging using 
fluorescent targets [19]. Even when expression of the individual genes of interest is static, sequential 
imaging of multiple luciferase proteins provides a convenient method for localizing expression profiles 
of each gene in vivo [20]. Sensors 2011, 11                       
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The  work  of  Audigier  and  colleagues  [21]  demonstrates  how  imaging  multiple  bioluminescent 
reporters  can  be  an  opportune  way  to  monitor  translational  dynamics  using  the  function  of  the 
fibroblast  growth  factor  two  internal  ribosomal  entry  site  on  neural  development  as  a  model.  To 
determine the associated ratios of cap-dependent to cap-independent translation, they cloned the RLuc 
gene upstream of the site and the FLuc gene downstream. By doing so, they were able to quantify and 
compare the levels of expression of each reporter protein independently from the same sample, helping 
to reduce sampling error. 
5.3. Multi-Component Bioluminescent Imaging 
Similar to multi-reporter BLI, multi-component BLI relies on the co-expression of an alternate 
imaging  construct,  however,  in  this  case  the  secondary  construct  is  not  itself  bioluminescent. 
Classically, the luminescent emission signal of a substrate amended luciferase protein can be harnessed 
to act as the excitation signal for an associated fluorescent reporter protein, negating the requirement 
for  treatment  with  a  background  stimulating  exogenous  light  source.  This  process,  known  as 
bioluminescence  resonance  energy  transfer  (BRET)  occurs  naturally  in  the  sea  pansy  Renilla 
reniformis and other marine animals [22], but can be used in research settings to boost the luminescent 
signal of a bioluminescent reporter, or, more popularly, to determine the interaction of two components 
of interest within a given system. 
A widely known example of the utility of this system was the use of BRET to demonstrate the 
presence of G protein coupled receptor dimers on the surface of living cells. By tagging a subset of  
β2-adrenergic  receptor  proteins  with  RLuc  and  a  subset  with  the  red-shifted  variant  of  green 
fluorescent protein, YFP, it was possible to detect both a luminescent and fluorescent signal in cells 
expressing both variants, but no fluorescent signal in cells expressing only YFP [23]. This illustrated 
the close proximity of the two constructs, since the energy transfer required for excitation of the YFP 
component can only be performed over very short distances and the lack of endogenous luminescence 
in the YFP excitation wavelength prevents background fluorescent production.  
In  some  cases,  the  secondary  component  is  not  a  fluorescent  compound  but  rather  a  
non-independently functional domain of the luciferase protein itself.  These types of constructs are 
easily  created  using  reporters  such  as  FLuc  that  have  distinct  N  (NLuc)  and  C  (CLuc)  terminal 
domains  joined  by  a  linker  region.  These  types  of  protein  structures  lend  themselves  nicely  to 
separation  into  distinct  components  that,  when  brought  together,  can  form  a  functional  
luciferase protein. 
First  described  by  Paulmurugan  et  al.  [24],  this  process  takes  advantage  of  the  lack  of  a 
bioluminescent signal in small animal tissue samples. The individual N and C terminal components of 
the FLuc protein are not capable of producing light independently of one another, however, when they 
were independently tethered to two proteins known to interact strongly, the researchers were able to 
demonstrate that bioluminescence could be restored upon substrate amendment. The complementation 
of a single luciferase protein as opposed to the adjoinment of a luciferase with a fluorescent partner 
does  not  require  the  pair  matching  of  a  luciferase/fluorescent  reporter  with  overlapping 
emission/excitation  wavelengths,  and  can  permit  co-visualization  with  other  reporters  in  a  single 
subject to permit multi-localization of groups of proteins. Sensors 2011, 11                       
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5.4. Bioluminescence as a Supplementary Imaging Technique 
As the technology for small animal imaging continues to increase in power and availability, there is 
an increasing movement towards combining multiple imaging techniques to improve the amount of 
detail that can be obtained from a single subject. While no single imaging technique can provide an 
investigator  with  a  comprehensive  picture  of  the  system  as  a  whole,  the  combination  of  multiple 
techniques such as computed tomography (CT), positron emission tomography (PET), and BLI can 
help to ―fill in the gaps‖ left by each approach in a rapid, sequential manner. The development of 
trimodal  fusion  proteins  that  are  capable  of  simultaneously  acting  as  signals  for  fluorescence, 
bioluminescence, and PET, and the introduction of combined clinical PET/CT scanners has made it 
possible  to  obtain  more  information  from  a  single  animal  subject  than  was  previously  believed  
possible [25]. 
6. Substrate Delivery Methods 
6.1. Required Substrate Amendment 
The most common bioluminescent proteins employed as targets for whole animal BLI, FLuc and 
RLuc, require the injection of a substrate compound in order to produce a bioluminescent signal. FLuc 
requires the injection of D-luciferin, while RLuc requires the injection of coelenterazine. It is only 
upon oxidation of these luciferin compounds that light is capable of being produced. The route of 
substrate injection can have influential effects on the emission of a luminescent signal so, although 
logistical concerns may be most pertinent to consideration for investigators, the method of injection 
should be considered in light of the proposed objectives of any study [26]. 
6.2. Intraperitoneal Injection 
The  convenience  of  intraperitoneal  injection  makes  it  an  attractive  option  for  the  majority  of 
researchers, however, following this route of injection the substrate must absorb across the peritoneum 
to reach the target expressing cells. Any variations in this rate of absorption can lead to variations in 
the resulting luminescent signal and can make reproducibility of results increasingly difficult [27]. In 
addition,  investigator  error  can  lead  to  injection  into  the  bowel,  causing  a  weak  or  non-existent 
luminescent  signal  that  can  be  confused  with  a  negative  result  [28].  Predictably,  intraperitoneal 
injection provides lower peak luminescence levels than subcutaneous injection when inducing light 
production in subcutaneous tumor models, however, it has been found that it can also overestimate 
tumor size when used to induce luminescence from intraperitoneal or spleen-localized tumors, owing 
to  direct  contact  between the luciferin and the  target  luciferase  expressing cells  [26]. The greater 
availability of the luciferin to the luciferase containing cells can increase the amount of bioluminescent 
output by allowing them greater access to the luciferin compound without prior diffusion through  
non-luciferase containing tissue and increasing the influx of the luciferin compound into the cell due to 
the resulting increased concentration gradient. 
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6.3. Intravenous Injection 
Intravenous  injection  can  be  used  to  systematically  profuse  a  test  subject  with  D-luciferin  or 
coelenterazine and expose multiple tissue locations to the substrate on relatively similar timescales. 
The  systemic  profusion  of  luciferin  allows  for  lower  doses  to  be  administered  to  achieve  similar 
luminescence intensities as would be seen using alternate injection routes [27], however, studies using 
radio-labeled  D-luciferin  have  indicated  that  the  uptake  rate  of  intravenously  injected  substrate  is 
actually  slower  in  gastrointestinal  organs,  pancreas,  and  spleen  than  would  be  achieved  using 
intraperitoneal  injection  [29].  While  the  intravenous  injection  of  substrate  can  quickly  perfuse 
throughout the entire subject, the resulting luminescent signal is of a much shorter duration than would 
be observed using alternate injection routes [26]. 
6.4. Subcutaneous Injection 
Subcutaneous injection can be used as an alternative to intraperitoneal injection while avoiding the 
signal attenuation shortcomings of the intravenous injection route. It has previously been demonstrated 
by  Bryant  et  al.  [30]  that  repeated  subcutaneous  injection  of  luciferin  can  provide  a  simple  and 
accurate model for monitoring brain tumor growth in rats.  It has also  been demonstrated that the 
repeated  subcutaneous  injection  of  D-luciferin  or  coelenterazine  into  an  animal  model  results  in 
minimal injection site damage and can provide researchers with bioluminescent signals that correlate 
well with intraperitoneal substrate injection luminescent profiles, albeit with a longer lag time prior to 
reaching tumor models in the intraperitoneal space [26]. 
7. BLI Applications 
The effectiveness, sensitivity, and sophistication of BLI methods and tools have resulted in an ever 
broadening  inventory  of  applications.  Tables  3  and  4  provide  a  snapshot  of  current  research  and 
developmental  activities  using  the  FLuc,  RLuc,  and  Lux  BLI  systems  and  the  following  sections 
present brief overviews of selected applications. 
7.1. Small Animal Models 
Small animal models, particularly mice, have become the preferred subjects for optical imaging 
experiments.  The  use  of  a  model  system  such  as  the  mouse  allows  researchers  to  look  at  
human-relevant  processes  in  a  well  documented  proxy  using  equipment  that  performs  similar 
functions, but is much less expensive and requires less space and resources than those employed within 
the medical field for human subjects. It also allows the researcher to move away from a cell culture 
setting where the system of interest is not able to be monitored under the same conditions at it would 
within the organism as a whole. This allows for the conduct of medically important research that can 
accelerate the transition to human medical use. One example of a common application of this type of 
research is the use of a bioluminescently-tagged cancer cell line to track the growth dynamics of the 
cancer  over  time  and  in  response  to  various  treatment  strategies.  Zhang  et  al.  [31]  have  recently 
demonstrated  how  these  two  avenues  can  be  investigated  simultaneously  by  using  FLuc-tagged  
MDA-MB-453 cells. By using a mouse model and injecting FLuc-tagged cancer cells, they were able Sensors 2011, 11                       
 
 
189 
to simultaneously compare and contrast multiple cancer models and at the same time evaluate the 
effect of several treatment courses. 
Virostko and colleagues [32] have demonstrated the usefulness of using a small animal model for 
direct measurement of human cells through the profusion of pancreatic Islets into mice expressing 
luciferase under the control of mouse insulin I promoter. This has allowed them to noninvasively look 
at changes in luminescent response to β cell mass under baseline and diabetic conditions. These types 
of medically relevant experiments demonstrate the advantages that can be achieved in a short period of 
time by using a small animal model rather than human subjects or cell culture. 
7.2. Tracking Cells 
BLI is extremely useful for longitudinal assessment of cell fate in vivo. When introduced into a 
living animal, bioluminescently-labeled cells can be repeatedly and noninvasively imaged over time. 
The intensity and location of the bioluminescent signal can provide insights into the abundance and 
spatial distribution of tagged cells in the living subject. In addition to visualizing tumor progression  
in  vivo  by  imaging  bioluminescent  cancer  cells  injected  into  living  animals,  investigators  have 
employed BLI to monitor the behaviors of stem cells [33-41], the response of immune cells in various 
diseases [42-45], and the rejection and engraftment of transplanted tissues [46-48]. 
Stem cell-based therapies hold promise in the treatment of cancer, cardiac disease, brain injury and 
other diseases. Before moving onto clinical trials, however, the behavior and mechanism of action of 
transplanted cells must be understood in vivo. Whole animal BLI allows repetitive and quantitative 
measurements  of  cells  of  interest,  providing  useful  information  on  cell  survival,  proliferation  and 
migration over time in the same living subject. For example, different types of stem cells have been 
extensively  used  in  cardiac  regeneration  therapies  [34,41,49,50].  Recently,  van  der  Bogt  and 
colleagues  compared  different  stem  cell  types  as  candidates  for  treatment  of  myocardial  
infarction [41,50]. They utilized BLI to assess in vivo fates of bioluminescently tagged bone marrow 
mononuclear cells (MNs), mesenchymal stem cells (MSCs), adipose stromal cells (ASCs), and skeletal 
myoblasts  (SkMb)  after  transplantation  into  a  murine  myocardial  infarction  model.  Their  results 
suggested  that  MNs  exhibited  higher  survival  rate  than  other  cell  types,  along  with  better  heart 
function. Stem cell researches will continually benefit from BLI as a fast and noninvasive tool to 
visualize cell fate in vivo. 
In addition to stem cells, immune cells are also attractive targets in research involving BLI. By 
labeling cells of interest with constitutively expressed luciferase, investigators are able to visualize 
target cell population trafficking throughout living subjects and homing to disease sites in response to 
various stimuli [51,52]. BLI enables monitoring immune effector cells (such as cytotoxic T cells and 
natural killer T cells) in various malignant diseases including graft-versus-host disease, cancer, heart 
diseases,  and neurological  diseases  [42,43,45,53-55]. As an example, investigators  employ  BLI to 
assess the fate of adoptively transferred T cells in tumor-bearing hosts to study tumor immunology and 
immunotherapy. In a recent study performed by Dobrenkov et al. [45], BLI was used to longitudinally 
track  human  prostate  cancer-specific  T  lymphocytes  in  a  murine  prostate  carcinoma  model.  By 
labeling tumor-targeted T cells with click beetle red luciferase and tagging tumor cells with RLuc, the 
authors were able to visualize T cell trafficking and tumor progression in the same animals at the same Sensors 2011, 11                       
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time.  This  model  demonstrates  the  application  of  multi-reporter  BLI  on  adoptive  T  cell-based 
immunotherapy and host response. By integrating multiple reporter probes, BLI has the potential to 
visualize complicated biological events involving multiple components of interest. 
7.3. Monitoring of Genes 
Regulation of gene expression is fundamental in cellular and molecular processes. Since more and 
more  genes  have  been  discovered  to  be  regulated  or  responsive  to  various  signals  during  disease 
progression, BLI has been facilitating the studies of conditional and spatiotemporal expression patterns 
of endogenous genes in living animals to provide better understandings of what is happening in vivo in 
real time. A common approach to monitor gene expression using BLI is to express a reporter gene (luc, 
for example) from the promoter of the gene of interest to test the expression of a particular gene. 
Alternatively, expressing the reporter gene under the control of regulatory elements responsive to a 
certain transcription factor can be used to investigate genes regulated by the same transcription factor. 
The expression level of the target gene is assessed by monitoring luciferase expression which can be 
interpreted  from  the  photon  output.  This  approach  has  been  widely  use  to  study  viral  gene  
expression [56], oncogene regulation [57], heat shock genes [58,59], genes involved in circadian clock 
rhythms [60], and genes involved in inflammation and various disease states [61-67]. As an example, 
Keller and coworkers [67] investigated the expression of glial fibrillary acidic protein (GFAP) during 
the  progression  of  amyotrophic  lateral  sclerosis  (ALS).  The  authors  generated  a  GFAP-luciferase 
reporter so that the regulation of GFAP could be visualized via bioluminescence output. Transgenic 
mice expressing the reporter construct were continuously imaged during the progression of ALS. Their 
findings demonstrated that GFAP induction in Schwann cells signified an onset of ALS. BLI facilitates 
the visualization of critical gene expression patterns in different stages of disease and advances the 
understanding of disease progression in vivo. 
BLI has not only been used to monitor endogenous gene expression, but also  has been widely 
utilized  to  visualize  transgene  delivery  and  expression  in  vivo  since  it  is  fast,  sensitive,  and 
noninvasive. Efficacy of gene transfer is evaluated by monitoring bioluminescent readout in the same 
living subject repeatedly over time without sacrificing animals. In recent years, investigators have 
employed BLI to assess many viral- and non viral-mediated gene transfer protocols [68-72]. 
7.4. Evaluating Protein Stability and Interaction 
BLI benefits not only studies of monitoring gene expression at the transcriptional level, but also 
assessing biological processes at the level of protein function and interaction. One method to evaluate 
protein expression and stability is to fuse a reporter protein (usually FLuc) to the protein of interest. 
The stability of the target protein can be monitored by the bioluminescent output from the luciferase 
function. Temporal changes in signal intensity tell investigators the dynamics of abundance of the 
protein in question. For example, Lehmann et al. [61] constructed a fusion protein containing HIF-1α 
and firefly luciferase to study the stabilization of HIF-1α in tumor development in vivo. HIFs (hypoxia 
inducible factors) regulate genes involved in cellular response to hypoxia and play a critical role in 
cancer biology [73]. It has been demonstrated that HIF-1α is more abundant in some tumor cells than 
in normal cells [74]. In this study, a murine colon cancer cell line, C51, was stably transfected with the Sensors 2011, 11                       
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fusion reporter and subcutaneously injected into nude mice to create an allograft model. BLI was used 
to  measure  total  photon  flux  in  HIF-1α-Fluc-expressing  tumors  as  the  tumors  grew.  Their  results 
revealed an increase in HIF-1α level in the early phase of tumor development and a dramatic decrease 
when the tumor volume was up to 1 cm
3. The HIF signaling pathway has become an attractive target 
for  anticancer  treatment  [73].  The  BLI  allograft  model  constructed  in  this  study  will  assist  drug 
development by providing a tool to visualize the efficacy of drugs in regulating HIF targets in vivo. 
In addition to monitoring the stability of a given protein, investigators also use BLI to assess the 
activities of general protein degradation machinery. In one example of such work, Luker et al. [75] 
generated a ubiquitin-luciferase fusion reporter to monitor the activity of 26S proteasome in vivo by 
assessing the degradation of the reporter. This change in activity was thus represented by the changes 
in bioluminescent output. A similar application of BLI has been its use in reporter complementation 
assays,  which  have  been  widely  used  to  assess  protease  activities  [75-78].  In  such  cases,  split 
fragments of luciferase are separated by a linker sequence that is recognized as a substrate by the 
particular protease of interest. In the presence of target enzyme, cleavage of the linker allows the split 
fragments  to  re-associate  back  to  a  fully  functional  protein  and  produce  a  bioluminescent  signal. 
Recently,  Wang  and  coworkers  [78]  used  this  approach  to  noninvasively  monitor  the  activity  of 
Hepatitis C virus (HCV) NS3/4A serine protease which is essential for viral reproduction in vivo. The 
reporter was constructed by separating the N-terminus and C-terminus of firefly luciferase and fusing 
them to interacting peptides (peptide A and peptide B), respectively, with NS3/4A cleavage sites. The 
reporter  plasmid  was  co-injected  with  a  plasmid  (pNS3/4A)  encoding  the  HCV  NS3/4A  protease 
sequence or a control plasmid into living mice to validate the reporter in vivo. BLI revealed an increase 
in  bioluminescent  output in  mice co-injected with pNS3/4A compared  to  mice co-injected with a 
vehicle  control  plasmid.  Moreover,  the  authors  demonstrated  the  ability  of  this  reporter  to  screen 
NS3/4A inhibitors in living animals.  
Many  biological  events  involve  protein-protein  interactions  that  can  be  affected  by  various 
physiological conditions. Traditionally, protein interactions were studied by means of a two-hybrid 
system  in  yeast.  However,  complete  understanding  of  protein  interactions  requires  assessing  the 
subjects  within  relevant  cellular  microenvironments.  BLI  allows  in  vivo  visualization  of  protein 
interactions as they happen in living animals in real time. In such cases, luciferase is split into two  
non-functional fragments (NLuc and CLuc), each of which is fused to one of the two proteins of 
interest. Interaction between query proteins brings NLuc and CLuc fragments close to each other to 
form  a  fully  functional  luciferase.  When  the  split  reporter  is  introduced  into  living  animals, 
bioluminescent output can be read as an indicator of protein interactions in vivo. Paulmurugan et al. [24] 
for the first time demonstrated the application of split firefly luciferase complementation BLI to image 
MyoD-Id interaction in living mice. Later, the same group generated a split synthetic Renilla luciferase 
complementation assay to image drug-modulated heterodimerization of two human proteins in vivo [79]. 
Recently,  Luker  and  colleagues  [80]  successfully  utilized  this  approach  to  image  activation  and 
inhibition of chemokine receptor CXCR4 signaling in breast cancer metastasis in vivo by detecting 
interactions between CXCR4 and β-arrestin. This study established a new imaging model to probe 
CXCR signaling pathways and to screen for inhibitors in living animals. 
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Table 3. Selected BLI applications of firefly and Renilla luciferases (FLuc and RLuc). 
Applications  Examples  References 
Cell trafficking 
(survival, proliferation, 
migration, and 
function) in living 
animals 
Stem cells (SCs), such as hematopoietic SCs, embryonic 
SCs, mesenchymal SCs, bone marrow mononuclear cells, 
and muscle SCs 
[33-41,49,50,81,82] 
Immune effector cells such as cytokine-induced killer cells 
and NK-T cells 
[42,43,45,51,53,55] 
Transplanted tissues  [46-48] 
Noninvasive imaging 
of tumor development 
Tumor growth, metastasis, and response to therapies  [25,55,83-90] 
In vivo imaging of gene 
expression (conditional, 
spatial, and temporal 
patterns) 
In vivo control of HIV promoter  [56] 
HIF-1 transcriptional activity in tumor hypoxia  [61,62,73,91,92] 
Hsp70 expression during heat shock and laser irradiation  [58,59,93,94] 
Cox-2 gene expression   [63, 64]  
Hes1-Luc expression to assess somite segmentation clock  [95] 
P53 expression and screening for antitumor compounds  [96] 
Per2 expression in CNS circadian clock  [60] 
TGF-β transcriptional activity in breast cancer bone 
metastasis 
[65] 
GFAP expression in neurological disease  [66,67,97,98] 
HO-1 expression in hepatic ischemia  [99] 
TLR2 response in brain injury and inflammation  [100] 
MYC oncogene inactivation in liver cancer  [57] 
Smad signaling in injury and neurodegeneration  [101,102] 
Evaluation of gene 
therapy (gene transfer 
and expression after 
delivery) in living 
animals 
In vivo imaging of hydrodynamically dosed gene transfer  [68] 
In utero delivery of adeno-associated viral vectors  [69,103,104] 
Plasmid-mediated gene therapy for muscular dystrophy  [70] 
siRNA-mediated gene silencing  [72] 
Real-time, in vivo 
monitoring of 
inflammation and 
infection 
Viral infection and evaluation of virus vaccines  [105-109] 
Parasitic and fungal infections  [110-114] 
Biomaterial-associated infection  [115] 
Monitoring  
protein-protein 
interaction in living 
animals 
CXCR4 and β-arrestin interaction in breast cancer  [80] 
MyoD-Id protein interaction in living mice  [24] 
Rapamycin-modulated dimerization of two proteins  [79] 
Gal4-FLuc transgenic mice as universal reporters for 
protein-protein interaction (e.g., p53 and large T antigen) 
[116] 
Monitoring protein 
stability and function 
in vivo 
Complementation Luc reporter to detect caspase-3 activity 
and monitoring of apoptosis 
[76,77] 
Proteasome activity and proteasome inhibitor screening  [75] 
Furin (an endoprotease) activity in breast cancer  [117] 
Complementation Luc assay to detect hepatitis C virus 
NS3/4A serine protease activity in vivo 
[78] 
Complementation Luc assay to assess HIF-1α stability and 
function in tumor hypoxia 
[118] 
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Table 4. Selected BLI applications of bacterial luciferase (Lux). 
Organism   Application  References 
Human embryonic kidney 
(HEK293) cells 
Whole animal imaging  [119] 
Escherichia coli  Detection of E. coli O157:H7 in food and water  [120] 
In vivo imaging of E. coli colonization in mice  [121] 
Screening for interaction between antibiotics  [122] 
In vivo imaging of E. coli in wound infections  [123] 
Salmonella  Monitoring the role of nitric oxide in tumor therapy  [124] 
Noninvasive imaging of Salmonella invasion  [125-128] 
Testing the susceptibility of neonate to vaccine  [129] 
Pseudomonas aeruginosa  In vivo imaging of P. aeruginosa wound infection and evaluation 
of treatment 
[130] 
Streptococcus pneumoniae  Real-time monitoring of the pharmacodynamics of gemifloxacin  [131] 
Monitoring pneumococcal infection in the lungs of live mice  [132] 
Staphylococcus aureus  Monitoring of S. aureus infection in living mice  [133] 
Noninvasive monitoring of bacterial contamination on 
biomaterial surfaces and the related immune response  
[134] 
Assessing efficacy of antibiotics against bacterial biofilm 
formation in live mice 
[135] 
Visualization of intracellular S. aureus replication and response 
to antibiotic treatment 
[136] 
Listeria monocytogenes  Monitoring infection over time, visualization of bone narrow as a 
niche for L. monocytogenes during the latent period 
[137] 
Bifidobacterium breve 
UCC2003 
Tracking Bifidobacterium in mice in vivo  [138] 
Bacillus anthracis  In vivo monitoring of B. anthracis spore germination in mice  [139] 
Yersinia enterocolitica  In vivo assessment of Y. enterocolitica colonization and infection  [140] 
8. Recent Advances 
It is no surprise that with increasing interest and publication rates, more investigators are becoming 
involved  in  whole animal  BLI  research.  With the increased demand for improved techniques  and 
technologies comes the advances that move the field forward. One of the long standing problems has 
been the necessity for repeated injection of a substrate compound when FLuc or RLuc are employed as 
target  reporter  proteins.  In  order  to  reduce  the  amount  of  sequential  injections  required  to  illicit 
bioluminescent output, a method has recently been adopted that encapsulates the D-luciferin substrate 
of  FLuc into a liposome, which can then be tailored to  release the substrate at  either a rapid,  or 
gradually increasing rate. Intratumoral injections of quick-release liposomes allowed for an initial burst 
of detectable light, while intravenous injection of slow-release liposomes lead to a slow increase in 
radiance  over  4–7  hours  [141].  This  choice  of  fast  or  prolonged  luciferin  release  can  provide 
researchers with  customizable options  to  reduce the strain  of repeated  substrate injection on their 
animal models. Sensors 2011, 11                       
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To  alleviate  the  potential  resolution  problems  associated  with  imaging  small  metastatic  tumor 
formation  in  living  tissues,  it  has  recently  been  demonstrated  that  the  naturally  secreted  Gaussia 
luciferase (GLuc) protein can be used as a proxy for overall tumor burden. When tumor cells are 
tagged with the gene driving production of GLuc, the resulting protein product will be secreted into the 
bloodstream where it can then be imaged and subsequently correlated to overall tumor cell prevalence. 
In addition to demonstrating the feasibility of using GLuc to track system-wide metastatic prevalence, 
it can also be used to continuously monitor for treatment response without the need to isolate and 
image individual areas [142], making it an excellent proxy for quickly evaluating the effectiveness of 
anticancer compounds over time in vivo. 
Figure 1. In vivo comparison of the FLuc and Lux reporter systems in a mouse model. 
Following  subcutaneous  injection  of  both  (A)  FLuc-tagged  cells  and  luciferin  or  
(B) Lux-tagged cells alone, the subject is imaged to determine the size and placement of 
the target cellular population within the animal. Similar experiments can be performed for 
(C) FLuc or (D) Lux-tagged cells following intraperitoneal injection. Although the average 
radiance of the FLuc cells is greater than that of Lux cells (note inset scale values), the low 
background  detection  ofsmall  animal  BLI  allows  for  similar  localization  of  cellular 
populations within the subject. 
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There  has  also  been  recent  success  in  adapting  the  Lux  system  for  autonomous  function  in 
mammalian cells (Figure 1). The Lux system is unique because it is capable of synthesizing all of its 
required substrate components from endogenously available cellular components. This circumvents the 
problems associated with differential injection routes and the dynamic luminescent expression profiles 
associated with repeated substrate injection using alternate luciferase systems. It has now been shown 
that  mammalian  codon-optimized  lux  genes  can  be  expressed  in  mammalian  cells  and  produce 
detectable bioluminescent signals at a wavelength of 490 nm over periods of days when constitutively 
induced.  When  mammalian  cells  expressing  bioluminescent  signal  from  the  lux  genes  are 
subcutaneously injected into small animal models, they are able to function as tumor mimics that can 
combine the substrate-less detection characteristics of fluorescent reporters with the low background 
levels of bioluminescent reporter systems [119]. The ability to perform whole animal BLI without 
exogenous substrate addition will open the door for continuous, real-time imaging of animal subjects 
and provide investigators with a new luciferase for multiple reporter studies, increasing the usefulness 
of  this  technique.  Because  of  the  reagentless  nature  of  Lux  expression,  it  can  easily  be  used  in 
conjunction with existing reporter systems, prior to or following injection of the requisite substrate or 
introduction of an excitation wavelength of the chosen co-reporter system(s). In addition, the lack of a 
dynamic bioluminescent production rate in response to substrate addition allows the target populations 
of cells to be correlated to bioluminescent output at any time point during an experiment [119]. 
9. Conclusions 
In  the  relatively  short  period  of  time  since  its  introduction,  whole  animal  BLI  has  become  an 
invaluable  technique  for  the  noninvasive  monitoring  of  small  animal  subjects  that  has  yielded 
invaluable  contributions  to  a  variety  of  scientific  fields.  The  majority  of  BLI  experiments  take 
advantage of the well-characterized FLuc or RLuc luciferase proteins, and when used in conjunction 
with alternate imaging technologies, they can provide extremely thorough and sophisticated datasets. 
However,  one  must  take  care  to  select  the  appropriate  route  of  substrate  injection  upon 
supplementation of their associated substrate compounds. Despite the shortcomings of the currently 
available luciferase systems, they can often be adapted to provide information that would previously 
remain hidden from view, and recent advances in the field that can increase detection of small tumors, 
improve regulation of substrate availability, or negate it entirely make the future of BLI bright indeed. 
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